

Contents

1 Epidemiology

Andrew F. Olshan

1.1	Descriptive Epidemiology	1
1.2	Risk Factors	2
1.2.1	Pregnancy and Childhood Factors	2
1.2.2	Medication Use	3
1.2.3	Lifestyle Exposures	3
1.2.4	Parental Occupation and Environmental Exposures	4
1.3	Conclusions	4
	References	5

2 Screening for Neuroblastoma

William G. Woods

2.1	Introduction	7
2.2	The Rationale for Neuroblastoma Screening	7
2.3	Early Pioneering Studies Investigating Neuroblastoma Screening in Japan	8
2.4	Initial North American and European Neuroblastoma Screening Trials	9
2.5	Follow-up Studies from Japan and Europe	11
2.6	Definitive Controlled Trials from Quebec and Germany	11
2.6.1	Studies, Designs, and Logistics	11
2.6.2	Studies' Results	15
2.7	Biologic, Psychologic, Economic, and Clinical Aspects of Neuroblastoma Screening	17
2.7.1	Biologic Aspects	17
2.7.2	Psychologic Aspects	17
2.7.3	Economic Aspects	17
2.7.4	Clinical Implications	18
2.8	Conclusions	18
	References	18

3 Genetics

John M. Maris, Garrett M. Brodeur

3.1	Introduction	21
3.2	Associated Genetic Conditions	21
3.3	Constitutional Chromosomal Abnormalities	22
3.4	Hereditary Neuroblastoma	23
3.5	Genetic Studies of Familial Neuroblastoma	25
3.6	Conclusions	25
	References	26

4 Molecular Cytogenetics

Manfred Schwab

4.1	Introduction	27
4.2	Classical Cytogenetics	27
4.3	Oncogene Expression Profiling	28
4.4	"Neuroblastoma Suppressor Genes" and Loss of Heterozygosity	29
4.4.1	Chromosome 1p Deletion	29
4.4.1.1	One or More "Tumor Suppressor Gene" Loci in 1p	31
4.4.2	Deletion of 11q	31
4.4.2.1	Chromosome 11 Deletion and 17q Gain	32
4.4.3	LOH of Additional Chromosomes	32
4.4.4	LOH and Tumor Suppressor Genes: an Evasive Connection or Flawed Hypothesis?	32
4.5	Comparative Genomic Hybridization	34
4.6	Tumor Cell Ploidy	34
4.7	Conclusion	35
	References	35

5 Molecular and Developmental Biology of Neuroblastoma

Akira Nakagawara

5.1 Neural Crest Development and Neuroblastoma	41
5.1.1 Genes of Neural Development and Molecular Targets of Neuroblastoma	41
5.1.1.1 Bone Morphogenetic Proteins	43
5.1.1.2 <i>MASH1/hASH1</i>	43
5.1.1.3 Phox2a and Phox2b	44
5.1.1.4 Id	44
5.1.1.5 <i>MYCN</i>	45
5.2 Molecular Bases of Differentiation and Programmed Cell Death	45
5.2.1 Molecular Aspect of Spontaneous Regression	45
5.2.2 Neurotrophic Factors and Their Receptors	46
5.2.2.1 Neurotrophins and Their Receptors in Neuroblastoma	46
5.2.2.2 Neurotrophin Signaling in Neuroblastoma	46
5.2.3 GDNF Family Receptors	48
5.2.4 Other Factors and Receptors	48
5.2.5 Functional Role of p53 Family Genes	48
5.2.6 Apoptotic Signals in Neuroblastoma	50
5.3 Conclusions	50
References	51

6 Cellular Heterogeneity

Robert A. Ross

6.1 Introduction	55
6.2 Neural Crest Differentiation	55
6.3 Neuroblastoma Cellular Heterogeneity	56
6.4 N-type Neuroblastic Cells	56
6.5 S-type Non-Neural Cells	57
6.6 I-type Stem Cells	58
6.7 Transdifferentiation	59
6.8 Conclusions	60
References	60

7 Clinical Presentation

Frank Berthold, Thorsten Simon

7.1 Introduction	63
7.2 Diagnosis	64
7.2.1 Diagnostic Tumor Tissue	64

7.3 Clinical Presentation	65
7.3.1 Symptoms	65
7.3.1.1 Frequent Symptoms	65
7.3.1.2 Rare but Characteristic Symptoms	66
7.3.2 Tumor Markers	67
7.3.2.1 Catecholamine Metabolites	68
7.3.2.2 Neuron-Specific Enolase	68
7.3.2.3 Ferritin	68
7.3.2.4 Lactate Dehydrogenase	68
7.3.2.5 Other Tumor Markers	68
7.3.3 Primary Tumors	69
7.3.3.1 Sites of the Primary Tumor	69
7.3.4 Metastases	69
7.3.4.1 Metastatic Sites	69
7.3.4.2 Bone Marrow Assessment	70
7.3.4.3 Definition of Cortical Bone Metastases	72
7.4 Differential Diagnosis	72
7.4.1 Small Blue Round Cell Tumors	72
7.4.2 Adrenal Hemorrhage in the Newborn	72
7.4.3 Nephroblastoma	73
7.4.4 Esthesioneuroblastoma (Olfactory Neuroblastoma)	73
7.4.5 Ganglioneuroma, Pheochromocytoma, Paraganglioma, Chemodectoma	73
7.5 Clinical and Laboratory Evaluation	73
7.5.1 Staging	73
7.5.2 Biological Types of Neuroblastoma	75
7.5.2.1 Maturative Subtype	75
7.5.2.2 Regressive Subtype	76
7.5.2.3 Progressive Subtype	77
7.5.3 Prognostic Risk Groups	77
7.5.4 Response Criteria	82
7.6 Conclusions	82
References	83

8 Pathology of Peripheral Neuroblastic Tumors

Hiroyuki Shimada, Inge M. Ambros

8.1 Introduction	87
8.2 Historical Overview	88
8.3 Basic Morphology	88
8.3.1 Neuroblastoma (Schwannian Stroma-poor)	89
8.3.2 Ganglioneuroblastoma, Intermixed (Schwannian Stroma-rich)	91
8.3.3 Ganglioneuroma (Schwannian Stroma-dominant)	91
8.3.4 Ganglioneuroblastoma, Nodular (Composite, Schwannian Stroma-rich/ Stroma-dominant and Stroma-poor)	91

8.4	Prognostic Classification	92
8.5	Biological Relevance	92
8.5.1	Schwannian Development in Neuroblastic Tumors	92
8.5.2	Correlation of Histopathology with <i>MYCN</i> Amplification and <i>trkA</i> Expression	93
8.5.3	Composite Tumor	93
8.6	Conclusion	94
	References	94

9 Molecular Pathology of Neuroblastic Tumors Based on Genome-wide Expression Analysis

William L. Gerald

9.1	Introduction	97
9.2	Clinical Issues	98
9.3	Technical Aspects of Gene Expression Analysis	98
9.3.1	Transcript Profiling Methods	98
9.3.2	Data Analysis	100
9.3.3	The Impact of Tissue Heterogeneity on Gene Expression Analysis	100
9.4	Gene Expression Analysis of NB	100
9.4.1	The NB Transcriptome and Its Relationship to Neural Crest Development	100
9.4.2	Gene Expression Associated with Clinically Relevant Subtypes of NB	103
9.4.3	Molecular Pathology of <i>MYCN</i> Amplification	103
9.4.4	Distinct Molecular Features of NB Discovered Through Gene Expression Analysis	105
9.5	Conclusion	106
	References	106

10 Anatomic and Functional Imaging

Sara J. Abramson, Barry L. Shulkin

10.1	Introduction	109
10.2	Imaging Modalities	109
10.2.1	Ultrasonography	109
10.2.2	Computerized Axial Tomography	110
10.2.3	Magnetic Resonance Imaging	112
10.2.4	Bone Scan	113
10.2.5	MIBG Scintigraphy	113
10.2.6	Octreotide Scanning	115
10.2.7	Positron Emission Tomography Scanning	115
10.2.8	Other Tracers	115

10.3	Disease Evaluation	116
10.3.1	Primary Site	116
10.3.2	Local Invasion	116
10.3.3	Distant Metastases	116
10.3.3.1	Bone Metastases	116
10.3.3.2	Bone-Based, Dural-Based, Leptomeningeal, and Brain Metastases	116
10.3.3.3	Marrow Metastasis	117
10.4	Prenatally Diagnosed Neuroblastoma	118
10.5	Stage-4S Neuroblastoma	118
10.6	Evaluation of Disease Response	120
10.7	Conclusion	120
	References	120

11 Treatment of Neuroblastoma

11.1 Low-Risk Neuroblastoma

Brian H. Kushner, Susan L. Cohn

11.1.1	Introduction	124
11.1.2	Clinical Presentation	124
11.1.3	Clinical Staging	125
11.1.4	Biologic Prognostic Markers	125
11.1.5	Treatment	125
11.1.5.1	Localized Tumors with No Regional Spread	126
11.1.5.2	Regionally Invasive Unilateral Localized Tumors	127
11.1.5.3	Stage 4S	128
11.1.6	Future Directions	129
11.1.7	Conclusion	129

References 129

11.2 Intermediate-Risk Neuroblastoma

Brian H. Kushner, Susan L. Cohn

11.2.1	Introduction	131
11.2.2	Clinical Presentation	131
11.2.3	Clinical Staging	133
11.2.4	Biologic Prognostic Markers	133
11.2.5	Treatment	133
11.2.5.1	Treatment for Stage-3 Neuroblastoma	134
11.2.5.2	Treatment for Stage-4S Neuroblastoma	134
11.2.5.3	Treatment of Infant Stage-4 Neuroblastoma	135
11.2.6	Future Directions	136
11.2.7	Conclusion	136

References 137

11.3 High-Risk Neuroblastoma

Katherine K. Matthay, Nai-Kong V. Cheung

11.3.1	Treatment Approach for High-Risk Disease	138
11.3.2	Induction Therapy	139
11.3.3	Local Control	141
11.3.4	Consolidation Therapy	142
11.3.5	Therapy of Minimal Residual Disease	144
11.3.6	Conclusion	145

References 145

11.4 The Role of Surgery in the Treatment of Neuroblastoma

Michael P. La Quaglia

11.4.1	Introduction	149
11.4.2	History	149
11.4.3	Staging	151
11.4.3.1	Stage 1	151
11.4.3.2	Stage 2	152
11.4.3.3	Stage 3	152
11.4.3.4	Stage 4	153
11.4.4	Risk Status and Surgical Intervention	155
11.4.4.1	Low-Risk Patients	156
11.4.4.2	Intermediate Risk	156
11.4.4.3	High Risk	156
11.4.4.3.1	Gross Total Resection.	156
11.4.4.3.2	Rationale for Gross Total Resection in High-Risk Patients	156
11.4.4.3.3	Local Control	157
11.4.5	Surgical Complications and Mortality	157
11.4.6	Surgical Technique	158
11.4.6.1	Initial Biopsy	158
11.4.6.2	Cervical Lesions	159
11.4.6.3	Cervico-Thoracic Lesions	159
11.4.6.4	Mediastinal Tumors	159
11.4.6.5	Lesions in the Upper Abdomen and Retroperitoneum	159
11.4.6.6	Pelvic Tumors	159
11.4.7	Conclusion	160

References 161

11.5 Radiation Therapy

Suzanne L. Wolden, Daphne A. Haas-Kogan

11.5.1	Background	164
11.5.2	Radiation Approach According to Risk Stratification	164
11.5.2.1	Low- and Intermediate-Risk Disease	164
11.5.2.2	Intermediate-Risk Disease	164
11.5.2.3	Stage-4S Disease	165
11.5.2.4	High-Risk Disease	165
11.5.3	Radiation Techniques	167
11.5.3.1	General Technical Considerations	167
11.5.3.2	Intraoperative Radiation Therapy	169
11.5.4	Side Effects of Radiation	170
11.5.5	Conclusion	171

References 171

11.6 Stem Cell Transplantation

Stephan A. Grupp

11.6.1	Introduction	173
11.6.2	Autologous Transplant in Neuroblastoma	174
11.6.2.1	Children's Cancer Group 3891	174
11.6.2.2	Experimental HDC/SCR	175

11.6.3	PBSC Collection	177
11.6.3.1	Vascular Access	177
11.6.3.2	Collection	178
11.6.3.3	Techniques for Stem Cell Mobilization	178
11.6.3.4	Target Dose for PBSC Infusion	179
11.6.3.5	Processing and Storage of PBSC	180
11.6.3.6	Tumor Cell Purging	181
11.6.3.7	Storage	182
11.6.4	Conclusion	182

References 182

11.7 Minimal Residual Disease Measurement

Irene Y. Cheung, Peter F. Ambros

11.7.1	Introduction	185
11.7.2	Techniques in the Detection of Tumor Cells in the Hematopoietic System	186
11.7.2.1	Histology/Cytology	186
11.7.3	Detection Methods for MRD	186
11.7.3.1	Immunocytology/ Immuno histochemistry	186
11.7.3.2	Automatic Immunofluorescence Detection Techniques	187
11.7.3.3	Reverse Transcription-Polymerase Chain Reaction	188
11.7.3.3.1	Real-Time Quantitative RT-PCR	188
11.7.3.3.2	Molecular Targets	188
11.7.3.3.3	Perspectives on Molecular Detection	188
11.7.4	Clinical Relevance of MRD	189
11.7.5	Future Directions	190

References 191

12 Treatment of Relapsed and Refractory Neuroblastoma

Katherine K. Matthay, Brian H. Kushner

12.1	Introduction	193
12.2	Treatment Strategies for Resistant Disease	195
12.2.1	Primary Refractory Disease	195
12.2.2	Early Relapse	196
12.2.3	Late Relapse	196
12.2.4	Multiply Relapsed Disease	196
12.3	Cytotoxic Chemotherapeutic Agents	196
12.3.1	Alkylating and DNA Cross-Linking Agents	197
12.3.1.1	Ifosfamide and Cyclophosphamide	197
12.3.1.2	Melphalan Combined with Buthionine Sulfoximine	197
12.3.1.3	Platinum Compounds	198
12.3.1.4	Temozolomide	198
12.3.1.5	Tirapazamine	199

12.3.2	Topoisomerase Inhibitors	199
12.3.2.1	Irinotecan	199
12.3.2.2	Topotecan	200
12.3.2.3	Pyrazoloacridine	200
12.3.2.4	Rebeccamycin	201
12.4	Tumor-Targeted Biologic Agents	201
12.4.1	Retinoids	201
12.4.2	Tyrosine Kinase Inhibitors	201
12.4.3	Modulators of Apoptotic Pathway and Angiogenesis	201
12.4.3.1	Anti-Angiogenic Agents	201
12.4.3.2	Arsenic Trioxide	202
12.4.3.3	Demethylating Agents	202
12.4.3.4	Histone Deacetylase Inhibitors	202
12.5	Immunologic Therapy	203
12.5.1	Anti-GD2	203
12.5.2	Interleukins	203
12.5.3	Vaccines	204
12.6	¹³¹I-Metaiodobenzylguanidine	204
12.7	Conclusion	204
	References	205

13 Management of Neurologic Complications

Kim Kramer, Michael R. Pranzatelli

13.1	Introduction	213
13.2	Epidural Neuroblastoma	213
13.3	Metastatic Disease to the Central Nervous System	216
13.4	Opsoclonus–Myoclonus	217
13.4.1	Immunology	218
13.4.2	Pharmacology	218
13.4.3	Laboratory Testing	218
13.4.4	Treatment	219
13.4.4.1	Neuromodulation	219
13.4.4.2	Adjunctive Therapy	220
13.4.4.3	Precautions	220
13.5	Treatment-Related Neurologic Complications	220
13.6	Conclusions	220
	References	221

14 Immunology and Immunotherapy

Nai-Kong V. Cheung, Paul M. Sondel

14.1	Introduction: The Case for Immunotherapy	223
14.2	The Immunobiology of Neuroblastoma	224
14.3	How Neuroblastoma Escapes the Innate and Adaptive Immune Systems	225

14.4	Humoral Immunotherapy	226
14.4.1	Effector Mechanisms of MAb	226
14.4.2	Clinical Application of MAb	227
14.4.2.1	Naked MAb	227
14.4.2.2	Antibody in Combination with Cytokines	229
14.4.2.3	Antibody Immunoconjugates	229
14.4.3	Humoral Vaccines	232
14.4.3.1	Ganglioside-KLH Vaccines	232
14.4.3.2	Anti-Idiotype Vaccine	232
14.5	Cellular Immunotherapy	232
14.5.1	Activation of NK and NKT Cells	232
14.5.2	Activation of MHC-Restricted T Cells	233
14.5.3	Pre-clinical and Clinical Testing of T-cell Based Therapy in Neuroblastoma	233
14.5.3.1	Immunostimulants	233
14.5.3.2	Tumor Vaccines	233
14.5.3.3	Adoptive Therapy Using Autologous Cytotoxic Lymphocytes	234
14.5.3.4	Adoptive Therapy Using Allogeneic Lymphocytes	234
14.6	Conclusions	235
	References	235

15 Differentiation and Retinoids

Carol J. Thiele, C. Patrick Reynolds

15.1	Introduction	243
15.1.1	Neural Crest Development	243
15.1.2	NB as a Neural Crest Derivative	244
15.1.3	NB and Adrenal Medullary Development	244
15.1.4	Neural Crest Gene Expression During Development	245
15.1.5	MYCN in Neural Crest Development	245
15.2	Neurotrophins in Neural Crest Development	245
15.2.1	TrkA and NB	246
15.2.2	TrkB and NB	247
15.3	Differentiation	247
15.3.1	Retinoids	247
15.3.2	Retinoic Acid Receptors	248
15.4	13-cis-Retinoic Acid	249
15.4.1	High-Dose, Pulse, 13-cis-RA	250
15.4.2	13-cis-RA vs All Trans-Retinoic Acid	250
15.4.3	Post-Consolidation 13-cis-RA Therapy for High-Risk NB	250
15.5	Fenretinide	253
15.6	Conclusions	254
	References	254

16 Angiogenesis

Darrell J. Yamashiro, Susan L. Cohn

16.1	Introduction	257
16.2	Vascularity in Neuroblastoma	258
16.3	Expression of Proangiogenic Factors	258
16.3.1	VEGF and VEGF Receptors	258
16.3.2	Matrix Metalloproteinases	259
16.4	Expression of Angiogenesis Inhibitors	260
16.4.1	Pigment Epithelium-Derived Factor	260
16.4.2	Secreted Protein Acidic and Rich in Cysteine	260
16.4.3	Thrombospondin-1	260
16.5	Regulation of Angiogenesis by <i>MYCN</i>	261
16.6	Preclinical Testing of Antiangiogenic Agents	261
16.6.1	VEGF Blockade	261
16.6.2	TNP-470	261
16.6.3	Endostatin	261
16.7	Conclusions	262
	References	263

17 Experimental Therapeutics and Preclinical Models

Jennifer K. Peterson, Peter J. Houghton

17.1	Introduction	267
17.2	Heterotransplant Models	268
17.2.1	Cytotoxic Agents	268
17.2.2	Signal Transduction Inhibitors	270
17.2.3	Angiogenesis Inhibitors	271
17.2.4	Viral-Based Therapies	271
17.2.5	Immunotherapy and Radioimmunotherapy	272
17.3	Transgenic Models	272
17.4	Syngeneic Models	273
17.5	Conclusion	273
	References	274

18 Late Effects of Treatment

Caroline Laverdière, James Gurney,
Charles A. Sklar

18.1	Introduction	277
18.2	Long-Term Complications for Low- and Intermediate-Risk Neuroblastoma Survivors	278
18.2.1	Musculoskeletal	278
18.2.2	Neurological	278
18.3	Long-Term Complications for Survivors of High-Risk Neuroblastoma	279
18.3.1	Audiological	279
18.3.2	Endocrine	280
18.3.2.1	Thyroid Function	280
18.3.2.2	Reproductive Endocrine Function	281
18.3.2.3	Growth	282
18.3.3	Musculoskeletal Complications and Neurological Deficits	282
18.3.4	Dental	282
18.3.5	Pulmonary	282
18.3.6	Cardiac	283
18.3.7	Renal	283
18.3.8	Neurocognitive	283
18.3.9	Subsequent Malignant Neoplasms	284
18.4	Health-Related Quality of Life	284
18.5	Conclusion	285
	References	285

19 Perspectives and Future Directions

Nai-Kong V. Cheung, Susan L. Cohn

	References	291
--	------------	-----

	Subject Index	293
--	---------------	-----